Summit跌完康方生物跌:尚未抵达“金标准”的依沃西,难道真被高估了?

医药研究社
03 Jun

股价被依沃西OS数据拖累。来源|医药研究社自去年康方生物宣布,其自主研发的PD-1/VEGF双抗新药依沃西成为全球首个且唯一在III期单药头对头临床研究中击败K药(帕博利珠单抗)的药物,该公司在资本市场可以说越来越“吃香”。据悉,2022年康方生物股价一度跌至12港元/股以下,今年则一度超过105港元/股。而每一次依沃西的临床数据披露,都在牵动市场情绪:若超出预期,鲜花和掌声自然不会少;若不及预期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10